Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Treatment (SVR12) — 100.0; 96.0 percentage of particpants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.2 percentage of participants

Primary: Plasma Minocycline Level — 421 ng/ml

Primary: Number of Participants by Best Clinical Response Experienced — 20; 6; 6; 7 Participants

Primary: Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes — -1.0376; -0.4614 log change in colony forming units

Primary: Glycemic Control as Determined by the Change in Absolute HbA1c Level — -3.16; -2.00 Percent A1C

Primary: Number of Patients With Anal Erosion Within 14 Days After Insertion of FMS — 5; 5 Participants

Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting…

Primary: Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24 — 6.89; 6.90; 6.91; -2.19 units on a scale — p=< 0.001

Primary: Progression-free Survival — 16 Months

Primary: Ocular Itching at Onset of Action (15 Minutes Post-dose) — 1.33; 0.99; 2.11; 2.90 units on a scale

Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 697; 249; 736; 281 Participants

Primary: A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment. — 28.8; 31.5…

Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants